Key result
Preoperative antiplatelet therapy before acute type A aortic dissection repair was associated with higher mortality compared to no therapy (26% vs 10%; OR 6.808; 95% CI 1.554-29.828; P=0.011).
Why the study?
Sudden chest pain in acute type A aortic dissection can lead to misdiagnosis as acute coronary syndrome and subsequent antiplatelet therapy, but its effects on clinical outcomes remain unclear.
Does preoperative antiplatelet therapy increase mortality and bleeding complications in patients undergoing surgery for acute type A aortic dissection?
Cohort (n=3,092)
Yes
Does preoperative antiplatelet therapy increase mortality and bleeding complications in patients undergoing surgery for acute type A aortic dissection?
Odds Ratio: 6.808 (95% CI 1.554–29.828)
Absolute Event Rate: 26% vs 10%
p-value: p=0.011
Inadvertent preoperative antiplatelet therapy in patients with acute type A aortic dissection is associated with significantly increased bleeding, transfusion requirements, and early mortality.
No takes yet. Share an insight, caveat, or question.
Urges caution with preoperative antiplatelet use in acute type A aortic dissection; hypothesis-generating pending prospective confirmation.
Jiang et al. (2021) conducted a cohort in Acute Type A Aortic Dissection (ATAAD) (n=3,092). Preoperative antiplatelet therapy (aspirin, clopidogrel, or both) vs. No antiplatelet therapy was evaluated on Mortality (OR 6.808, 95% CI 1.554-29.828, p=0.011). Preoperative antiplatelet therapy before acute type A aortic dissection repair was associated with higher mortality compared to no therapy (26% vs 10%; OR 6.808; 95% CI 1.554-29.828; P=0.011).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: